Released Sep 16, 2019, after the close
10-Q filed Sep 16, 2019, 47 days after period end · 0001654954-19-010776
Q3 2019 · 10-Q
Revenue$4.97M$4.97M +7.2% vs Q3 2018−3.6% vs Q2 2019
Net Income$431.16K$431.16K −41.0% vs Q3 2018−39.1% vs Q2 2019
EPS, diluted—
Gross Profit$1,565,924−1.8%
Operating Income$360,696−50.0%
Operating Cash Flow-$627,300N/M
Free Cash Flowderived-$636,702N/M
Margins · derived
Gross margin31.5%−2.9 pt vs Q3 2018
Operating margin7.3%−8.3 pt vs Q3 2018
Net margin8.7%−7.1 pt vs Q3 2018
What the release said
The release
Same quarter
| Metric | Q3 2019 | Q3 2018 | Q3 2017 | Q3 2016 |
|---|---|---|---|---|
| Revenue | $4.97M | $4.63M | $3.98M | — |
| Net Income | $431.16K | $730.63K | -$162.98K | -$130.47K |
| EPS Diluted | — | $0.03 | -$0.01 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR